Drug Profile

Research programme: extended-release tri-specific T cell engaging therapeutics - Harpoon Therapeutics

Alternative Names: Extended-release tri-specific T cell engager platform; TriTAC-XR; TriTAC-XR platform

Latest Information Update: 15 Mar 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Harpoon Therapeutics
Class Antineoplastics; Immunotherapies; Recombinant fusion proteins
Mechanism of Action Cytokine inhibitors; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Haematological malignancies; Solid tumours

Most Recent Events

11 Mar 2024 Harpoon Therapeutics has been acquired by Merck and Co
31 Dec 2022 Harpoon Therapeutics has patents pending for TriTAC-XR platform, prior to December 2022
19 Apr 2022 Harpoon Therapeutics intends to announce the nomination of an IND candidate from the TriTAC-XR platform in the second half of 2022

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com